Merck Reports $16.6 Billion in Q2 2026 Global Sales, Up 5%
Merck announced its global total sales for the second quarter of 2026 reached $16.6 billion, marking a 5% increase year-over-year. Excluding foreign exchange impacts, the company's sales grew by 4%. The company reported a GAAP earnings per share (EPS) loss of $0.54 and a non-GAAP EPS loss of $0.13 for the quarter. Both the GAAP and non-GAAP EPS losses were significantly influenced by a $2.31 per share charge related to the acquisition of Terns Pharmaceuticals. These financial results provide insight into Merck's performance and strategic investments during the second quarter of 2026.
Merck's Q2 2026 financial report highlights a modest 5% global sales increase, demonstrating resilience in its core business operations. The significant per-share charge attributed to the Terns Pharmaceuticals acquisition underscores the financial complexities and upfront costs associated with strategic mergers and acquisitions. Investors will likely scrutinize the long-term value proposition of this acquisition against its immediate impact on profitability metrics. Future performance will depend on the successful integration of Terns Pharmaceuticals and its contribution to Merck's product pipeline and market position in the evolving pharmaceutical landscape.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.
